Are you Dr. Bradner?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 129 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
Dana-Farber Cancer Institute
Boston, MA 02115Phone+1 617-632-6629Fax+1 617-632-5168
Summary
- Dr. James Bradner, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute, Brigham and Women's Faulkner Hospital, and South Shore Hospital.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005- Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1999
Certifications & Licensure
MA State Medical License 2002 - 2025
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2011
Publications & Presentations
PubMed
- Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.Pawel K Mazur, Alexander Herner, Stephano S Mello, Matthias Wirth, Simone Hausmann
Nature Medicine. 2024-07-01 - 5 citationsAuthor Correction: An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.George P Souroullas, William R Jeck, Joel S Parker, Jeremy M Simon, Jie-Yu Liu
Nature Medicine. 2024-06-01 - 4 citationsHigh-throughput approaches to uncover synergistic drug combinations in leukemia.Emma J Chory, Meng Wang, Michele Ceribelli, Aleksandra M Michalowska, Stefan Golas
SLAS Discovery. 2023-06-01
Press Mentions
Genetic Study Provides First-Ever Insight into Biological Origin of SchizophreniaJune 25th, 2020- Real-Time Transferrin-Based PET Detects MYC-Positive Prostate CancerJune 7th, 2020
SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in CancerJune 6th, 2019- Join now to see all
Grant Support
- Selective Inhibition Of HDAC6 In Cancer TherapyNational Cancer Institute2008–2011
